[go: up one dir, main page]

CY1108274T1 - Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων - Google Patents

Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων

Info

Publication number
CY1108274T1
CY1108274T1 CY20081100886T CY081100886T CY1108274T1 CY 1108274 T1 CY1108274 T1 CY 1108274T1 CY 20081100886 T CY20081100886 T CY 20081100886T CY 081100886 T CY081100886 T CY 081100886T CY 1108274 T1 CY1108274 T1 CY 1108274T1
Authority
CY
Cyprus
Prior art keywords
glp
peptide
disease
gastrental
glucogenic
Prior art date
Application number
CY20081100886T
Other languages
English (en)
Inventor
Dominique P Bridon
Nissab Boudjellab
Roger Leger
Martin Robitaille
Karen Thibaudeau
Julie Carette
Original Assignee
Conjuchem Biotechnologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Biotechnologies Inc. filed Critical Conjuchem Biotechnologies Inc.
Publication of CY1108274T1 publication Critical patent/CY1108274T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αυτή αφορά παράγωγα ομοιάζοντος με γλυκογόνο πεπτιδίου 2 (GLP-2). Συγκεκριμένα, η εφεύρεση αυτή αφορά παράγωγα GLP-2 πεπτιδίου που έχουν εκτεταμένη in vivo ημίσεια ζωή, για την θεραπεία ή πρόληψη γαστρεντερικών διαταραχών ή ασθενειών όπως η ασθένεια φλεγμονώδους εντέρου και άλλων γαστρεντερικών λειτουργιών, οποιουδήποτε τμήματος της γαστρεντερικής οδού, από τον οισοφάγο μέχρι τον πρωκτό.
CY20081100886T 2001-02-16 2008-08-20 Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων CY1108274T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26927601P 2001-02-16 2001-02-16
EP02700079A EP1360202B1 (en) 2001-02-16 2002-02-15 Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders

Publications (1)

Publication Number Publication Date
CY1108274T1 true CY1108274T1 (el) 2014-02-12

Family

ID=23026568

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100886T CY1108274T1 (el) 2001-02-16 2008-08-20 Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων

Country Status (14)

Country Link
US (3) US7112567B2 (el)
EP (2) EP1980572A1 (el)
JP (4) JP4280070B2 (el)
AP (1) AP1886A (el)
AT (1) ATE396202T1 (el)
AU (1) AU2002233089B2 (el)
CA (1) CA2436399A1 (el)
CY (1) CY1108274T1 (el)
DE (1) DE60226702D1 (el)
DK (1) DK1360202T3 (el)
EA (1) EA006160B1 (el)
ES (1) ES2307718T3 (el)
PT (1) PT1360202E (el)
WO (1) WO2002066511A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
PT1412384E (pt) * 2001-06-28 2008-03-28 Novo Nordisk As Formulação estável de glp-1 modificado
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
JP2007525425A (ja) * 2003-03-24 2007-09-06 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−２誘導体
JP2007524592A (ja) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
JP4936884B2 (ja) * 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
DK1687019T3 (en) * 2003-11-20 2018-02-12 Novo Nordisk As Propylene glycol peptide formulations that are optimal for production and use in injection devices
BRPI0510117A (pt) 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc método para purificação de conjugados de albumina
US8710181B2 (en) * 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
WO2006050244A2 (en) 2004-11-01 2006-05-11 Nps Allelix Corp. Treatment of short bowel syndrome patients with colon-in-continuity
CA2586771A1 (en) * 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinotropic peptides
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
EP1948785B1 (en) * 2005-10-24 2014-01-15 Janssen Biotech, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008056155A1 (en) * 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
CA2698976A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009075859A2 (en) * 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
WO2009158704A2 (en) * 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
JP5908478B2 (ja) * 2010-08-30 2016-04-26 エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
WO2013164484A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US20190055279A1 (en) * 2015-10-28 2019-02-21 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
EP3481855B1 (en) 2016-07-11 2023-09-06 OPKO Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
CN110088125B (zh) 2016-12-09 2023-10-03 西兰制药公司 酰化的glp-1/glp-2双重激动剂
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
EP3689898A4 (en) * 2017-09-28 2021-06-16 Hanmi Pharm. Co., Ltd. Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative
CN108395469A (zh) * 2018-02-01 2018-08-14 滨海吉尔多肽有限公司 一种假脯氨酸二肽的合成方法
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
KR20210126088A (ko) 2019-02-11 2021-10-19 옵코 바이오로직스 리미티드 지속성 glp-2 유사체
CN114945560B (zh) 2019-10-07 2024-08-13 卡尔优普公司 Gpr119激动剂
EP4106727A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Pharmaceutical formulations
JP2023516187A (ja) 2020-02-28 2023-04-18 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1160380A (en) * 1966-12-22 1969-08-06 Ford Motor Co Vehicle Engine Arrangement.
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
DE3241416A1 (de) * 1982-01-19 1983-07-28 Josef Gartner & Co, 8883 Gundelfingen Isolierverglasung
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
DE69226077T2 (de) 1991-04-05 1998-12-03 Genentech, Inc., South San Francisco, Calif. PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
CZ281630B6 (cs) 1992-06-12 1996-11-13 Des-Tyr Dynorphin Partnership Analogy des-tyr dynorfinu
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5496007A (en) * 1994-05-13 1996-03-05 Reece; Cecil L. Device for holding out-sized documents
EP0788371A1 (en) 1994-08-26 1997-08-13 LEE, Nancy M. Analgesic method with dynorphin analogues truncated at the n-terminus
US5789379A (en) * 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
CA2215152A1 (en) 1996-01-12 1997-07-17 Redcell Canada, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
CA2257119A1 (en) 1996-06-05 1997-12-11 Boehringer Mannheim Gmbh Exendin analogues, processes for their production and pharmaceutical preparations containing them
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
AU4351897A (en) 1996-09-16 1998-04-02 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
EP1012186B1 (en) * 1996-12-06 2002-07-17 Amgen Inc., Use of a kgf protein product(s) and a glp-2 protein product(s) for the preparation of a medicament
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6723530B1 (en) * 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JP2001513512A (ja) 1997-08-08 2001-09-04 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンディン作動剤化合物
DE69839946D1 (de) 1997-11-07 2008-10-09 Conjuchem Biotechnologies Inc Methoden zum Screening von Affinitätsmarker-Bibliotheken
EP1007561B1 (en) 1997-11-07 2002-04-17 Conjuchem, Inc. Novel conjugates of opioids and endogenous carriers
US6437092B1 (en) * 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
DE69826705T2 (de) 1997-11-12 2006-02-23 Alza Corp., Palo Alto Verfahren zur dermalen verabreichung von polypeptiden
ES2297902T5 (es) 1997-11-14 2013-07-09 Amylin Pharmaceuticals, Inc. Compuestos novedosos agonistas de exendina
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
AU3247799A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504527A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
EP1062229A1 (en) 1998-03-09 2000-12-27 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
AU748496B2 (en) 1998-03-23 2002-06-06 Conjuchem, Inc. Local delivery of long lasting therapeutic agents
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) * 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6451974B1 (en) * 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
ATE318835T1 (de) * 1999-05-17 2006-03-15 Conjuchem Inc Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US7144854B1 (en) * 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
EP1171582A2 (en) 1999-05-17 2002-01-16 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DE60000665T3 (de) 1999-05-17 2009-10-29 ConjuChem Biotechnologies Inc., Montreal Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
JP2003508501A (ja) 1999-09-07 2003-03-04 コンジュケム，インコーポレーテッド 生物学的結合のための肺送達
US7090851B1 (en) * 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
EA006484B1 (ru) 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
ATE396202T1 (de) * 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60216151T2 (de) 2001-05-31 2007-09-27 ConjuChem Biotechnologies Inc., Montreal Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
US6882816B2 (en) * 2002-02-19 2005-04-19 Matsushita Electric Industrial Co., Ltd. Developing device with developer circulating path
JP2006514607A (ja) 2002-07-31 2006-05-11 コンジュケム，インコーポレーテッド 長時間持続性ナトリウム排泄増加性ペプチド誘導体
ES2328579T3 (es) 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
BRPI0510117A (pt) * 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc método para purificação de conjugados de albumina
WO2007053946A1 (en) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
US20090312259A1 (en) 2009-12-17
JP4280070B2 (ja) 2009-06-17
DK1360202T3 (da) 2008-09-22
CA2436399A1 (en) 2002-08-29
AU2002233089B2 (en) 2005-12-22
WO2002066511A3 (en) 2003-03-06
EP1360202A2 (en) 2003-11-12
DE60226702D1 (de) 2008-07-03
US7737251B2 (en) 2010-06-15
ES2307718T3 (es) 2008-12-01
EP1980572A1 (en) 2008-10-15
JP2009035568A (ja) 2009-02-19
US20060217304A1 (en) 2006-09-28
EA200300857A1 (ru) 2003-12-25
JP2010150276A (ja) 2010-07-08
US7112567B2 (en) 2006-09-26
JP2008179652A (ja) 2008-08-07
AP1886A (en) 2008-09-20
EA006160B1 (ru) 2005-10-27
ATE396202T1 (de) 2008-06-15
JP2004532819A (ja) 2004-10-28
EP1360202B1 (en) 2008-05-21
AP2005003310A0 (en) 2005-06-30
WO2002066511A2 (en) 2002-08-29
PT1360202E (pt) 2008-09-01
US20040248782A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
BR9914044A (pt) ésteres tetrahidropirido
HUP0301835A2 (hu) Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
ATE305932T1 (de) Rapanycin29-enole
CY1118363T1 (el) Αντισωματα που ανοσοειδικως συνδεονται προς blys
CY1112962T1 (el) 1,2-διαρυλο βενζιμιδαζολες για την αντιμετωπιση ασθενειων, οι οποιες σχετιζονται με την ενεργοποιηση μικρογλοιων
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
TR201909741T4 (tr) Kolon temizleme bileşimleri.
CY1110954T1 (el) Ημιστερεες βλεννοκολλωδεις φαρμακοτεχνικες μορφες
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
LU92175I2 (fr) Lixisénatide
CY1109454T1 (el) Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
CY2013004I2 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
CY1114919T1 (el) Anti-mag ανθρωποποιημενα αντισωματα και οι χρησεις τους για την αντιμετωπιση του εγκεφαλικου επεισοδιου
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR9809185A (pt) Diidropiranos fundidos
BR9711306A (pt) Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis